Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/31/25
End: 07/31/29
Due: 07/31/30
ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Phase: N/A
Priority: Normal
Start: 05/31/22
End: 05/01/26
Due: 05/01/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer | NCT07026279 | Amplia Therapeutics Limited | user2@example.com | None | 2025-07-31 | 2029-07-31 | 2030-07-31 | - | - | 2025-07-14 |
| ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | NCT05355298 | Amplia Therapeutics Limited | user2@example.com | None | 2022-05-31 | 2026-05-01 | 2027-05-01 | - | - | 2025-07-14 |